DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Phase 2

Completed

Conditions: Smoldering Myeloma
Smoldering Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-10-31

Last Posted Date: 2023-06-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 51

Registration Number: NCT02279394

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 6 locations

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care

Recruiting

Conditions: Melanoma
NSCLC

First Posted Date: 2014-10-30

Last Posted Date: 2023-12-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 840

Registration Number: NCT02279004

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Recruiting

Conditions: Waldenstrom Macroglobulinemia
B-cell Malignancy, Low-grade
Myelodysplastic Syndrome With Low-grade Lesions
IgG Monoclonal Gammopathy of Uncertain Significance
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Hematological Malignancies
Chronic Lymphocytic Leukemia (CLL)
Myelodysplastic Syndromes
Smoldering Multiple Myeloma

First Posted Date: 2014-10-21

Last Posted Date: 2024-08-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10000

Registration Number: NCT02269592

Locations: 🇺🇸
Dana Farber Cancer Institute at St. Elizabeth's, Brighton, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute at South Shore, Weymouth, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute at Merrimack Valley, Methuen, Massachusetts, United States

and more 4 locations

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Phase 1

Completed

Conditions: Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions: Drug: TGR-1202
Drug: Ibrutinib

First Posted Date: 2014-10-20

Last Posted Date: 2024-11-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT02268851

Locations: 🇺🇸
Pacific Cancer Care, Monterey, California, United States
🇺🇸
St. Francis Hospital and Cancer Center, Hartford, Connecticut, United States
🇺🇸
Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States

and more 2 locations

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

Phase 2

Completed

Conditions: Prostate Adenocarcinoma
Prostate Cancer
High Risk Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Abiraterone Acetate
Drug: Prednisone
Drug: Leuprolide Acetate

First Posted Date: 2014-10-20

Last Posted Date: 2022-04-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 75

Registration Number: NCT02268175

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Impact of Cerebellar Mass Resection on Pain Processing

Completed

Conditions: Cerebellar Neoplasm

Interventions: Device: Medoc Advanced Medical Systems PATHWAY Model ATS
Procedure: Cold water bath
Device: MRI scanner
Other: Questionnaires

First Posted Date: 2014-10-10

Last Posted Date: 2018-02-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT02261649

Locations: 🇺🇸
Boston Children's Hospital, Waltham, Massachusetts, United States

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Phase 2

Completed

Conditions: Breast Cancer
Brain Tumor - Metastatic

Interventions: Drug: Cabozantinib
Drug: Trastuzumab

First Posted Date: 2014-10-09

Last Posted Date: 2021-05-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 36

Registration Number: NCT02260531

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Phase 2

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Ibrutinib
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2014-09-29

Last Posted Date: 2024-07-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 85

Registration Number: NCT02251548

Locations: 🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 5 locations

Impact of Radiation Therapy on Breast Conservation in DCIS

Completed

Conditions: DCIS

First Posted Date: 2014-09-25

Last Posted Date: 2019-09-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3436

Registration Number: NCT02248662

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States
🇺🇸
Dartmouth College, Hanover, New Hampshire, United States

and more 1 locations

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Phase 1

Completed

Conditions: Anaplastic Thyroid Cancer
Thyroid Cancer
Differentiated Thyroid Cancer

Interventions: Drug: MLN0128

First Posted Date: 2014-09-19

Last Posted Date: 2024-01-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT02244463

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Michigan Medical School, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy